### Anastrozole

**Section:** 8. Immunomodulators and antineoplastics  ➤  8.2. Antineoplastics and supportive medicines  ➤  8.2.4. Hormones and antihormones

**Indication**
- Malignant neoplasms of breast

**INN**
- Anastrozole

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Oral > Solid: 1 mg tablet

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2021 (TRS 1035)

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**
- Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: L02BG Aromatase inhibitors

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Anastrozole

**DrugBank**
- Anastrozole

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, L02BG Aromatase inhibitors, be specified as therapeutic alternatives under the square box listing for anastrozole on the EML.